Chlorprothixene is a thioxanthene (thiazine-class) antipsychotic drug with pharmacological effects similar to but weaker than chlorpromazine. It exhibits sedative, anxiolytic, and antidepressant properties, with relatively weak anticholinergic and antiadrenergic effects. Clinically, it is commonly used for schizophrenia accompanied by depressive or anxious symptoms, involutional psychosis, affective psychoses, depression, schizoaffective disorder, and anxiety neurosis. It is particularly effective in alleviating anxiety, tension, depression, negative symptoms, and sleep disturbances, but shows poor efficacy against catatonia and emotional blunting. It is especially ineffective for the simple and catatonic types of schizophrenia and demonstrates weaker antipsychotic activity against hallucinations and delusions compared to phenothiazine derivatives. It has also been reported to be used in the treatment of anxiety neurosis. Additionally, chlorprothixene has been shown to inhibit SARS-CoV replication in Vero76 cells and to reduce inflammation and prevent Pseudomonas aeruginosa infection in cystic fibrosis mouse models by restoring normal sphingosine levels through inhibition of acid sphingomyelinase (Asm).